Trials / Terminated
TerminatedNCT00366704
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
A Multicenter, Randomized, Double-blind, Parallel-group Fixed-dose Study of the Effect on Weight of Bifeprunox Versus Risperidone in the Treatment of Outpatients With Schizophrenia.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effect of bifeprunox or risperidone on the body weight of patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bifeprunox | .25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8) |
| DRUG | risperidone | 4mg, QD, 8 week treatment |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2006-08-21
- Last updated
- 2013-02-11
Locations
66 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00366704. Inclusion in this directory is not an endorsement.